Immunological studies and in vitro schistosomicide action of new imidazolidine derivatives

ORIGINAL PAPER

Immunological studies and in vitro schistosomicide action of new imidazolidine derivatives

Neves JKAL^I; Sarinho S^I; de Melo CML^II; Pereira VRA^II; de Lima MCA^I; Pitta IR^I; Albuquerque MCPA^{III, IV}; Galdino SL^I

^ILaboratory for Drug Design and Synthesis, Department of Antibiotics, Federal University of Pernambuco (UFPE), Recife, Pernambuco State, Brazil

^IIDepartment of Immunology, Aggeu Magalhães Research Center, Oswaldo Cruz Foundation (FIOCRUZ), Recife, Pernambuco State, Brazil

^IIIImmunopathology Laboratory Keizo Asami, Federal University of Pernambuco (UFPE), Recife, Pernambuco State, Brazil

^IVDepartment of Tropical Medicine, Federal University of Pernambuco (UFPE), Recife, Pernambuco State, Brazil

^{Correspondence to}

ABSTRACT

Schistosomiasis is a major public health problem with 207 million people infected and more than 779 million at risk. The drug of choice for treating schistosomiasis is praziquantel (PZQ); however, it is inefficient against immature forms of schistosomes. The aim of this study was to test new imidazolidine derivatives LPSF/PT09 and LPSF/PT10 against adult Schistosoma mansoni worms. IC50, cytotoxicity, immune response and cell viability assays were also available for these imidazolidines. Different concentrations of imidazolidine, from 32 to 320 ¼M, promoted motor abnormalities in breeding and unpaired worms, and death in 24 hours at higher concentrations. Although LPSF/PT09 and LPSF/PT10 did not affect IFN-³ and IL-10 production, they induced nitric oxide production and showed a similar behavior to praziquantel on cell death test. Thus, these new imidazolidine derivatives should undergo further study to develop schistosomiasis drugs.

Key words:Schistosoma mansoni , in vitro, imidazolidines.

INTRODUCTION

Parasites are an important group of human pathogenic organisms affecting the lives of approximately 2 billion people mostly in the tropics and subtropics in developing countries (1). Schistosomiasis is a major public health problem with 207 million people infected and further 779 million at risk. The disability caused by this chronic helminth infection was recently reassessed in order to correctly represent its previously underestimated high impact on public health (2-4).

Immunological studies in mice have described that resistance to schistosome reinfection mainly correlates with a Th1 response while pathology correlates with Th2 response (5). Cytokines such as IL-4, IL-13, TNF-α, and IFN-γ are closely linked to schistosomiasis disease and are prevalent in schistosome-associated fibrosis (6). Studies have shown that IL-10 correlates with morbidity control in humans, whereas higher levels of nitric oxide produced by macrophages display cytotoxic activity against parasites and play an important role in immune system modulation of parasitosis (7, 8).

So far, the reference drug for schistosomiasis treatment is praziquantel (PZQ), but it seems inefficient against immature forms and there are now reports of resistance in some strains which has worried world public health organizations (9, 10). Therefore many studies have been testing the effectiveness of new drugs against many strains of schistosomes (11, 12).

Imidazolidines and their derivatives comprise a substance class that has shown anti-convulsive and antiarrhythmic pharmacological activities. Furthermore, the imidazolidines have a methylene group very reactive to carbon-5 that allows the synthesis of many derivatives through aromatic aldehyde condensation (13).

Imidazolidines have been used as anti-schistosome agents in previous studies performed by our group (14-16). Here we investigated the action of two new imidazolidine derivatives, 5-(4-chloro-arylazo)-3-(4-chloro-benzyl)-4-thioxo-imidazolidine-2-ona (LPSF/PT-09) and 3-(4-chloro-arylazo)-5-(4-chloro-benzyl)-4-thyoxo-imidazolidine-2-one (LPSF/PT-10) against adult Schistosoma mansoni worms. Cellular viability test, cytotoxicity and immunomodulatory activity induced in vitro by these new compounds on immune spleen cells were also available.

MATERIALS AND METHODS

Compounds

Imidazolidine derivatives 5-(4-chloro-arylazo)-3-(4-chloro-benzyl)-4-thioxo-imidazolidine-2-one (LPSF/PT-09) and 3-(4-chloro-arilazo)-5-(4-chloro-benzyl)-4-thioxo-imidazolidin-2-one (LPSF/PT-10) were obtained through synthesis performed at the Laboratory for Drug Design and Synthesis, Federal University of Pernambuco, Brazil, which were duly identified by nuclear magnetic resonance of hydrogen, infrared and mass spectroscopy. The praziquantel was purchase from Sigma Chemical Co. (USA - lot 044K1032).

Parasites and Intermediary Hosts

BH (Belo Horizonte city, MG, Brazil) strains of S. mansoni that have been maintained in the Immunopathology Laboratory Keizo Asami (LIKA) were used throughout this study. The strains were kept after they had passed through Biomphalaria glabrata molluscs provided by the Department of Tropical Medicine (Federal University of Pernambuco).

Animals Used as Definitive Hosts

Female Swiss mice weighing 20 ± 2g were used; they were obtained and maintained at the animal facility of LIKA. Animals were infected by exposure to an S. mansoni cercarian suspension containing approximately 100 cercariae, using the tail immersion technique (17). Animals were housed in a controlled temperature and light environment, and were given water and commercial chow ad libitum. The experiments were approved by Ethics Committee for Animal Experimentation of the Federal University of Pernambuco.

Anti-S. mansoni Assay

For the in vitro test worms were maintained in RPMI-1640 medium (Sigma Chemical Co., USA) buffered to pH 7.5, supplemented with HEPES (20 mM), 10% fetal bovine serum, penicillin (100 U.mL^-1), and streptomycin (100 µg.mL^-1). Incubation was performed at 37°C in a humid atmosphere containing 5%CO₂. LPSF/PT-9 and LPSF/PT-10 imidazolidine derivatives were dissolved in 1.6% dimethyl sulphoxide (DMSO) and used in concentrations varying from 32 to 320 µM which were added to the medium containing the worms after a two-hour period of adaptation to the culture medium. Duplicates were carried out for each concentration. The parasites were kept for five days and monitored every 24 hours to evaluate their general condition: motor activity, alterations to the tegument, and mortality rate. The PZQ group used the same methodology, but the concentration ranged from 10 to 80 µM. Control worms were only treated with DMSO in RPMI 1640 medium.

Animals Used for Immunological, Cytotoxic, and Cellular Viability Assays

Male BALB/c mice (6 to 8 weeks old) were raised at the animal facility of the Oswaldo Cruz Foundation (Rio de Janeiro, Brazil) and maintained at the animal facility of the Aggeu Magalhães Research Center, Oswaldo Cruz Foundation, in Recife, Brazil. All mice were sacrificed and their spleens removed in accordance with the Oswaldo Cruz Foundation Commission for Experiments with Laboratory Animals (Ministry of Health, Brazil, 0266/05).

Spleen Cell Harvesting

Spleen cells were harvested according to a previous protocol (18). After killing the animal with CO₂ gas, the spleen of each mouse was removed aseptically and placed in a Falcon tube containing RPMI 1640 with fetal calf serum (complete medium). In a vertical flow, each spleen was transferred to a Petri dish where they were soaked. The cell suspensions obtained were transferred to Falcon tubes containing approximately 10 mL of incomplete medium per spleen, centrifuged at 4°C, 200 x g for five minutes. After discarding the supernatant, distilled water was added to the sediment to promote red blood cell lysis. The supernatant, containing no cellular debris was collected and centrifuged at 4°C, 200 x g for five minutes. The resulting sediment (containing cells) was re-suspended in complete RPMI 1640. An aliquot of each cell suspension was separated, diluted in trypan blue for quantification in a Neubauer chamber and cell viability was determined.

In vitro Cytotoxicity Assay

The cytotoxicity of the compounds was determined using BALB/c mice splenocytes (6 x 10⁵ cells.well^-1) cultured in 96-well plates containing RPMI 1640 medium (Sigma Chemical Co., USA) supplemented with 10% of fetal calf serum (FCS - Cultilab, Brazil), and 50 µg.mL^-1 of gentamycin (Novafarma, Brazil). Each imidazolidine was evaluated at six concentrations (1, 5, 10, 25, 50, and 100 µg.mL^-1), in triplicate in two independent assays. Cultures were incubated in the presence of ³H-thymidine (Amersham Biosciences, USA) (1 µCi.well^-1) for 24 hours at 37°C and 5% CO₂. The content of the plate was then harvested to determine ³H-thymidine ([³H]TdR) incorporation using a beta-radiation counter (β-matrix 9600^®, Packard, USA). Compound toxicity was determined by comparing the percentage of ³H-thymidine incorporation (as an indicator of cell viability) in imidazolidines-treated wells with untreated wells. Non-cytotoxic concentrations were defined as those where ³H-thymidine incorporation was 30% lower than untreated controls. Six concentrations were also used for praziquantel (1, 5, 10, 25, 50, and 100 µg.mL^-1).

Measurement of Cytokine Levels in Splenocyte Supernatants

Spleen cells were cultured in 24-well culture plates (TPP) at a density of 10⁶ cells.well^-1. Cytokines were quantified in 24-, 48-, 72-hour, and six-day supernatants from cultures stimulated with concanavalin A (Con A - 2.5 µg.mL^-1) and phytohemagglutinin (PHA - 5 µg.mL^-1) mitogens and PT-9 and PT-10 (1 µg.mL^-1), or maintained only in culture medium (control). Levels of IL-10 and IFN-γ were measured by sandwich ELISA, according to manufacturer's protocols. The monoclonal antibodies used were from an OptEIA^® Kit (BD Biosciences, USA), having previously been titered. Plates with 96 wells (Nalge Nunc International Corporation, Denmark) were sensitized with specific anti-cytokine antibodies (according to manufacturer's instructions) and incubated overnight at 4°C. Standard cytokines were added after serial dilution from their initial concentration (16000 pg.mL^-1). After washes, 50 µL of all samples and standards were added in duplicate and the plate incubated for two hours at room temperature. Subsequently, the specific antibodies were combined with biotin (according to manufacturer's instructions) and incubated for 90 minutes at room temperature. Revealer solution was added containing 2.2-azino-bis (3-ethylbenzothiazoline-6-sulphonic acid) diammonium salt (ABTS). Reaction was blocked with 1M sulphuric acid and the reading taken in a spectrophotometer (Bio-Rad 3550^®, Hercules, USA) at 415 nm. Sample concentrations were calculated in the linear region of the titration curve of cytokine standard curves, and final concentrations were expressed in pg.mL^-1, using Microplate Manager^® Version 4.0 software (Bio-Rad Laboratories, USA).

In vitro Nitrite Analysis

Mice spleen cells were used to evaluate nitrite concentration, when treated with Con A (2.5 µg.mL^-1), PHA (5 µg.mL^-1), LPSF/PT-9 and LPSF/PT-10 (1, 10, and 100 µg.mL^-1), and after 24, 48, 72 hours and six days of incubation. Culture media were carefully collected for subsequent measurement by Griess colorimetric method (19). NO concentration was estimated by the standard curve (3.12 - 100 µmol.mL^-1).

Analysis of Cellular Viability Using Annexin V-FITC and Propidium Iodide Staining

Immune spleen cells were treated with praziquantel (PZQ), LPSF/PT-9, or LPSF/PT-10 all at a 1 µg.mL^-1 concentration. These treated cells were maintained in culture in 24-well plates (TPP) for 24, 48 and 72 hours, each then analyzed for cellular viability. Cells without treatment were used as negative control. Subsequently, lymphocytes were centrifuged at 4°C, 450 x g for ten minutes. After discarding supernatant, 1 mL of 1x PBS was added to the sediment and centrifuged at 4°C, 450 x g for ten minutes. After again discarding supernatant, the resulting pellet was re-suspended in a binding buffer [10 mM HEPES (pH7.4), 150 mM NaCl, 5 mM KCl, 1 mM MgCl₂, and 1.8 mM CaCl₂] and annexin V conjugated with fluorescein isothiocyanate (FITC) (1:500) and propidium iodide (PI, 20 µg.mL^-1; 106 cells) was added to each cytometer tube.

Flow cytometry was performed on a FACSCalibur^® (Becton Dickinson Biosciences, USA) and analyzed using Cell Quest Pro^® software (Becton Dickinson Biosciences, USA). Analysis of results was performed on graphs by dot plot. Double-positive cells (Annexin-FITC+/PI+) were considered spleen cells in the late stage of apoptosis, whereas only PI+ cells were necrotic cells. Annexin-FITC+/PI- represented splenocytes in the early stage of apoptosis. Double-negative results were considered as viable cells.

Statistical Analysis

Data were analyzed using non-parametric tests. To detect differences between groups, the Mann-Whitney U test and Tukey t test were used. All results were expressed by mean values of groups ± standard deviations and were analyzed considering p < 0.05 as statistically significant.

RESULTS

PZQ Cytotoxicity Was Superior to Imidazolidine Derivatives

For the purpose of determining selectivity, imidazolidine derivative actions were tested against spleen cells from BALB/c mice (an effective method which for evaluating specific T lymphocyte cytotoxicity), using praziquantel as the standard drug. Cytotoxicity assays using immune mouse spleen cells showed that LPSF/PT-9 presented nontoxic effects at 10, 5, and 1 µg.mL^-1 concentrations and LPSF/PT-10 did not exhibit cytotoxicity at 5 and 1 µg.mL^-1 concentrations (Table 1). However praziquantel showed higher toxicity against splenocytes at all tested concentrations (Table 2). LPSF/PT-9 and LPSF/PT-10 also were tested against S. mansoni adult worms and results expressed in terms of IC₅₀ (µM) values. PZQ also was used as the reference schistosomicide drug. In vitro adult worm mortality was observed at different imidazolidine derivative concentrations. Imidazolidine derivatives did show activity against adult S. mansoni worms. LPSF/PT-09 induced 100% mortality at 320 µM concentration in the first 48 hours. The same behavior was present at 100 µM concentrations after 72 hours. LPSF/PT-10 induced 100% worm mortality in 24 hours at 320 µM concentration. The same behavior was seen at 200 and 100 µM concentrations after 72 hours. Oviposition by adult worms was also not seen at any of these imidazolidine concentrations. The control group remained viable throughout the whole observation period (Table 1).

LPSF/PT-9 and LPSF/PT-10 Did Not Produce IFN- γ and IL-10 Cytokines

For immunological assays we investigated IL-10 and IFN-γ cytokines and nitric oxide production on supernatants from cultures of splenocytes stimulated in vitro with LPSF/PT-9 and LPSF/PT-10 at 1 µg.mL^-1 concentrations. The immunological properties of mitogens phytohemagglutinin (PHA at 5 µg.mL^-1) and concanavalin A (Con A at 2.5 µg.mL^-1) were used as positive controls, and cells plus medium (without stimulus) were used as negative control. Although statistically higher values were produced for Con A and PHA mitogens at all experimental culture times (data not show), neither experimental imidazolidine was efficient in producing IL-10 and IFN-γ from culture supernatants.

LPSF/PT-9 and LPSF/PT-10 Induce Higher Nitrite Production Levels

The effects of NO-induced production in murine spleen cells were measured on in vitro cultures treated with LPSF/PT-9 and LPSF/PT-10 at 100, 10, and 1 µg.mL^-1 concentrations. Statistically higher values were observed for both LPSF/PT-9 and LPSF/PT-10 at 100 µg.mL^-1. At 24 hours, LPSF/PT-9 on 100 and 1 µg.mL^-1 concentrations showed higher values than control, and LPSF/PT-10 at 100 µg.mL^-1 was superior to control. Also at 24 hours, LPSF/PT-10 was statistically superior to LPSF/PT-9 at 100 µg.mL^-1 (Figure 1 - A). After 48 hours, LPSF/PT-9 and LPSF/PT-10 at 100 µg.mL^-1 were statistically superior to control and among themselves (Figure 1 - B). Although LPSF/PT-9 presented higher values, only LPSF/PT-10 at 100 µg.mL^-1 showed statistical difference to control at 72 hours (Figure 1 - C). At the final culture time, LPSF/PT-9 and LPSF/PT-10 at 100 µg.mL^-1 showed statistical difference to control. At six days we also observed that LPSF/PT-9 at 100 µg.mL^-1 was statistical superior to LPSF/PT-10 at 10 µg.mL^-1 (Figure 1 - D).

Low Cellular Death Induced by LPSF/PT-9 and LPSF/PT-10 Imidazolidines

Cellular viability was performed to measure cellular damage induced by imidazolidine derivatives; all compounds were used at a 1 µg.mL^-1 concentration. After 24 hours, the number of apoptotic cells was higher than cells in late apoptosis and necrotic cells. At this time, PZQ was statistically superior to LPSF/PT-9 and LPSF/PT-10 (Figure 2 - A), but not higher than control cells (without treatment). In late apoptosis, we observed that LPSF/PT-10 was superior to LPSF/PT-9 and PZQ, but not to controls. LPSF/PT-10 demonstrated higher quantities of necrotic cells than controls, PZQ, and LPSF/PT-9 (Figure 2 - B). At 48 hours, PZQ showed higher values than the other compounds. PZQ was superior to LPSF/PT-9 (Figure 2 - A) and LPSF/PT-10 at apoptosis, late apoptosis, and necrosis, but only in necrosis were these values statistically superior to controls (Figure 2 - B). The only time that presented a statistical difference in relation to controls for all composites tested was 72 hours. At apoptosis PZQ, LPSF/PT-9, and LPSF/PT-10 were superior to controls and PZQ was superior to LPSF/PT-10 (Figure 2 - A). PZQ and LPSF/PT-9 induced more late apoptosis than controls, and both were statistically superior to LPSF/PT-10. This behavior was similar in the necrosis assay, i.e., PZQ and LPSF/PT-9 were superior to controls and LPSF/PT-10 (Figure 2 - B).

DISCUSSION

Imidazolidine derivatives have been studied by several research groups. The main activities assigned to these compounds are antibacterial, antiamebic, anti-T. cruzi and anti-Schistosome (16, 20-22). We analyzed the cytotoxicity and immunological properties of two new imidazolidine derivatives, LPSF/PT-9 and LPSF/PT-10, against Schistosoma mansoni worms.

LPSF/PT-9 and LPSF/PT-10 were less cytotoxic and induced superior mortality in adult worms than praziquantel. But in relation to the absence of oviposition by adult worms and motor abnormalities, imidazolidines were similar to PZQ. Many drugs have been compared with praziquantel and their cytotoxicity and ability to kill adult S. mansoni worms has been shown as similar to praziquantel (23, 24). However, equally to praziquantel, the mechanism by which imidazolidines exert schistosomicide activity in vitro is still unclear. Many studies have demonstrated that low PZQ concentrations, in vitro, appear to impair the function of the worms' suckers and at higher concentrations increases the contraction (irreversibly at very high concentrations) of the worms' strobila (chain of proglottids), cause irreversible focal vacuolization with subsequent cestodal disintegration at specific sites of the cestodal integument (25-28). As well as these aspects, imidazolidines act on apoptotic cells with melanoma; their route was identified in S. mansoni and should be investigated as to their role in the death of these parasites (15, 16, 29).

Reports have shown a Th1 and Th2 response balance in schistosomiasis patients. Before treatment, patients in the acute phase, as well as those with the severe hepatosplenic form of the disease, have high levels of pro-inflammatory cytokines in their serum (IL-1, IL-6 and IFN-γ). On the other hand, patients with the intestinal clinical form have higher levels of IL-10 (5, 30). Furthermore, these same studies strongly suggest that resistance to infection is multifactorial and that it can not be clearly correlated with a single immune mechanism. Stephaniel (31) affirm that low concentrations of IL-10, IL-4, and TGF-β inhibit macrophage larvicidal activity, as well as nitric oxide (NO) production, in a synergistic mechanism. The induction of T-lymphocyte proliferation by mitogens involves both cell-cell interaction and molecular communication. One of the changes observed after stimulation of lymphocytes by mitogens like PHA or Con A, are increased ion fluxes and transport of other substrate across the plasma membrane. The consequences of increased K⁺, for example, include increased intracellular levels of Na²⁺ and Ca²⁺ in addition to decreased Mg²⁺ and K⁺ in PHA stimulated lymphocytes. This fact shows the requirement for calcium in lymphocyte activation and its participation in the process (32). The central event in PZQ activity on schistosomes may well be the phenomenon of calcium influx into the tegument which is observed within a couple of minutes of drug exposure. However, the mechanisms leading to this alteration in calcium homeostasis are not clear (33, 34).

In our study, imidazolidine derivatives did not induce significant production of IFN-γ or IL-10. However, the potent anti-schistosomiasis agent, nitric oxide, was strongly stimulated. Nitric oxide has been shown to only affect targets located very close to its source. This behavior is important to avoid toxicity to surrounding tissues and indicates that the larvicidal action of NO does not require interaction with other effector cell products (31). Against parasitosis, there is ample direct and indirect evidence that NO can act as an antischistosomal and, more broadly, antiparasitic molecule (35-37). NO produced by human white cells has been shown to kill larval schistosome parasites and has recently been shown to kill a multitude of eukaryotic and prokaryotic organisms, against which no other defense mechanism has, to our knowledge, been reported (35, 38, 39). In addition, studies have shown that compounds which induce nitric oxide release possess potential immunomodulatory properties (40). Here, we observed that LPSF/PT-9 and LPSF/PT-10 imidazolidines stimulated NO production by immune spleen cells and this behavior may indicate a possible immunostimulant activity induced by imidazolidine derivatives.

The two types of cellular death, apoptosis and necrosis, differ fundamentally in morphology, biochemistry and biological relevance. Apoptotic cells are generated in vast quantities in the central lymphoid organs, such as the thymus and bone marrow, and are removed daily by phagocytic cells for homeostasis maintenance of these tissues. On the other hand, cellular death by necrosis occurs, generally, as a response to injuries suffered by these cells that have ruptured the plasmatic membrane leading to homeostasis loss and a constituent release that starts an inflammatory response (41). However, the distinction between initial apoptosis, late apoptosis, and necrosis is still largely under discussion.

Damage to cell morphology in in vitro assays has been demonstrated by many drugs. Malheiros et al. (42) using trifluoperazine (TFP), dibucaine (DBC), and praziquantel observed cytotoxic effects, such as hemolysis and the release of membrane lipids, in human erythrocyte membranes in a dose-dependent mechanism. In our cellular death test, PZQ showed higher values at all experimental times and some results were superior to the imidazolidines when tested on immune spleen cells. But behavior between experimental composites was very similar, especially at 72 hours assay, indicating that similar routes may be activated in the induction of cell death for the compounds evaluated and the reference drug PZQ. However, we believe that more assays are needed to answer this question.

LPSF/PT-9 and LPSF/PT-10 imidazolidine derivatives displayed relevant antischistosomal activity in vitro, induced higher nitric oxide production by immune spleen cells, and showed similar behavior to praziquantel in the cellular death test. It is therefore possible that these new imidazolidine derivatives can be future candidates for schistosomiasis drugs, but further studies are needed to elucidate the mechanisms induced for this response. Understanding the mechanisms that mediate the effects these compounds have on the immune system will provide information that will make these compounds future candidates for schistosomiasis drugs.

ACKNOWLEDGEMENTS

The authors are grateful to the Federal Foundation for Brazilian Research and Development (FINEP), the Coordination Executive for the Improvement of Higher Education Personnel (CAPES), and The National Council for Scientific and Technological Development (CNPq) for their financial support.

Submission status

Received: November 25, 2010

Accepted: April 19, 2011

Abstract published online: April 26, 2011

Full paper published online: August 31, 2011

Conflicts of interest

There are no conflicts of interest

Financial source

The Federal Foundation for Brazilian Research and Development (FINEP), The Coordination Executive for the Improvement of Higher Education Personnel (CAPES), and The National Council for Scientific and Technological Development (CNPq) for provided financial grants

Ethics committee approval

This study was approved by the Ethics Committee for Animal Experimentation, Federal University of Pernambuco (process n. 007639/2007-12), in accordance with law 9.605, article 32, decree 3179, art 17.

• 1. Doenhoff MJ, Pica-Mattoccia L. Praziquantel for the treatment of schistosomiasis: its use for control in areas with endemic disease and prospects for drug resistance. Expert Rev Anti Infect Ther. 2006;4(2):199-210.
• 2. Chitsulo L, Engels D, Montresor A, Savioli L. The global status of schistosomiasis and its control. Acta Trop. 2000;77(1):41-51.
• 3. Steinmann P, Keiser J, Bos R, Tanner M, Utzinger J. Schistosomiasis and water resources development: systematic review, meta-analysis, and estimates of people at risk. Lancet Infect Dis. 2006;6(7):411-25.
• 4. Lammie PJ, Fenwick A, Utzinger J. A blueprint for success: integration of neglected tropical disease control programmes. Trends Parasitol. 2006;22(7): 313-21.
• 5. Correa-Oliveira R, Caldas IR, Martins-Filho OA, Carvalho Queiroz C, Lambertucci JR, Cunha-Melo JR, et al. Analysis of the effects of treatment of human Schistosoma mansoni infection on the immune response of patients from endemic areas. Acta Tropica. 2000;77(1):141-6.
• 6. Hoffmann KF, Wynn TA, Dunne DW. Cytokine-mediated host responses during schistosome infections; walking the fine line between immunological control and immunopathology. Adv Parasitol. 2002;52(1):265-307.
• 7. Falcão PL, Malaquias LC, Martins-Filho OA, Silveira AM, Passos VM, Prata A, et al. Human Schistosomiasis mansoni: IL-10 modulates the in vitro granuloma formation. Parasite Immunol. 1998;20(10):447-54.
• 8. Moncada S, Palmer RM, Higgs EA. Nitric oxide: physiology, pathophysiology, and pharmacology. Pharmacol Rev. 1991;43(1):109-42.
• 9. Ismail M, Botros S, Metwally A, William S, Farghally A, Tao LF, et al. Resistance to praziquantel: direct evidence from Schistosoma mansoni isolated from Egyptian villagers. Am J Trop Med Hyg. 1999;60(6):932-5.
• 10. Pica-Mattoccia L, Cioli D. Sex- and stage-related sensitivity of Schistosoma mansoni to in vivo and in vitro praziquantel treatment. Int J Parasitol. 2004;34(4):527-33.
• 11. Sayed AA, Simeonov A, Thomas CJ, Inglese J, Austin CP, Williams DL. Identification of oxadiazoles as new drug leads for the control of schistosomiasis. Nat Med. 2008;14(4):407-12.
• 12. Allam G. Immunomodulatory effects of curcumin treatment on murine schistosomiasis mansoni. Immunobiology. 2009;214(8):712-27.
• 13. Rossi MH, Zelnik R. Contribuição à química das imidazolidinadionas - síntese de ciclanilideno-hidantoínas. Arq Inst Biol. 2000;67(1):125-30.
• 14. Oliveira SM, Albuquerque MCPA, Pitta MGR, Malagueño E, Santana JV, Lima MCA, et al. A resposta do Schistosoma mansoni mantido in vitro frente a derivados imidazolidinônicos. Acta Farm Bonaerense. 2004;23(3):343-8.
• 15. Albuquerque MC, Silva TG, Pitta MG, Silva AC, Silva PG, Malagueño E, et al. Synthesis and schistosomicidal activity of new substituted thioxo-imidazolidine compounds. Pharmazie. 2005;60(1):13-7.
• 16. Pitta MG, Silva AC, Neves JK, Silva PG, Irmão JI, Malagueño E, et al. New imidazolidinic bioisosters: potential candidates for antischistosomal drugs. Mem Inst Oswaldo Cruz. 2006;101 Suppl 1:313-6.
• 17. Olivier L, Stirewalt MA. An efficient method for exposure of mice to cercariae of Schistosoma mansoni J Parasitol. 1952;38(1):19-23.
• 18. Pereira VR, Lorena VM, Da Silva AP, Coutinho EM, Silva ED, Ferreira AG, et al. Immunization with cytoplasmic repetitive antigen and flagellar repetitive antigen of Trypanosoma cruzi stimulates a cellular immune response in mice. Parasitology. 2004;129(Pt 5):563-70.
• 19. Ding AH, Nathan CF, Stuehr D. Release of reactive nitrogen intermediates and reactive oxygen intermediates from mouse peritoneal macrophages. Comparison of activating cytokines and evidence for independent production. J Immunol. 1988;141(7):2407-12.
• 20. Kalyanam N, Parthasarathy PC, Ananthan L, Manjunatha SG, Likhate MA. Studies on antiamoebic compounds. IV: Synthesis of hexahydropyrimidines and tetrahydroimidazoles. Indian J Chem. 1992;31(4):243-7.
• 21. Sharma V, Khan MS. Synthesis of novel tetrahydroimidazole derivatives and studies for their biological properties. Eur J Med Chem. 2001;36(7-8):651-8.
• 22. Caterina MC, Perillo IA, Boiani L, Pezaroglo H, Cerecetto H, González M, et al. Imidazolidines as new anti-Trypanosoma cruzi agents: biological evaluation and structure-activity relationships. Bioorg Med Chem. 2008;16(5):2226-34.
• 23. Dayan AD. Albendazole, mebendazole and praziquantel. Review of non-clinical toxicity and pharmacokinetics. Acta Trop. 2003;86(2-3):141-59.
• 24. Sayed AA, Simeonov A, Thomas CJ, Inglese J, Austin CP, Williams DL. Identification of oxadiazoles as new drug leads for the control of Schistosomiasis. Nat Med. 2008;14(4):407-12
• 25. Xiao SH, Catto BA, Webster Jr LT. Effects of praziquantel on different developmental stages of Schistosoma mansoni in vitro and in vivo J Infect Dis. 1985;151(6):1130-7.
• 26. Cioli D, Pica-Mattoccia L. Praziquantel. Parasitol Res. 2003;90 Suppl 1:3-9.
• 27. Martin RJ. Mode of action of anthelmintic drugs. Vet J. 1997;154(1):11-34.
• 28. Ali BH. A short review of some pharmacological, therapeutic and toxicological properties of praziquantel in man and animals. Pak J Pharm Sci. 2006;19(2):170-5.
• 29. Dubois F, Caby S, Oger F, Cosseau C, Capron M, Grunau C, et al. Histone deacetylase inhibitors induce apoptosis, histone hyperacetylation and up-regulation of gene transcription in Schistosoma mansoni Mol Biochem Parasitol. 2009;168(1):7-15.
• 30. Malaquias LC, Falcão PL, Silveira AM, Gazzinelli G, Prata A, Coffman RL, et al. Cytokine regulation of human immune response to Schistosoma mansoni: analysis of the role of IL-4, IL-5 and IL-10 on peripheral blood mononuclear cell responses. Scand J Immunol. 1997;46(4):393-8.
• 31. Stephaniel J. Role of nitric oxide in parasitic infections. Microbiol Rev. 1995;59(4):533-47.
• 32. Hadden JW. Transmembrane signals in the activation of T-lymphocytes by lectin mitogens. Mol Immunol. 1988;25(11):1105-12.
• 33. Cioli D. Chemotherapy of Schistosomiasis: an update. Parasitol Today. 1998;14(10):418-22.
• 34. Greenberg RM. Are Ca2+ channels targets of praziquantel action? Int J Parasitol. 2005;35(1):1-9.
• 35. Brunet LR. Nitric oxide in parasitic infections. Int Immunopharmacol. 2001;1(8):1457-67.
• 36. Colasanti M, Gradoni L, Mattu M, Persichini T, Salvati L, Venturini G, et al. Molecular bases for the anti-parasitic effect of NO (Review). Int J Mol Med. 2002;9(2):131-4.
• 37. Rivero A. Nitric oxide: an antiparasitic molecule of invertebrates. Trends Parasitol. 2006;22(5):219-25.
• 38. James SL, Glaven J. Macrophage cytotoxicity against schistosomula of Schistosoma mansoni involves arginine-dependent production of reactive nitrogen intermediates. J Immunol. 1989;143(12):4208-12.
• 39. Brophy PM, Pritchard DI. Immunity to helminths: ready to tip the biochemical balance? Parasitol Today. 1992;8(12):419-22.
• 40. Ahmed SF, Oswald IP, Caspar P, Hieny S, Keefer L, Sher A, et al. Developmental differences determine larval susceptibility to nitric oxide-mediated killing in a murine model of vaccination against Schistosoma mansoni Infect Immun. 1997;65(1):219-26.
• 41. Korhonen R, Kosonen O, Hämäläinen M, Moilanen E. Nitric oxide-releasing compounds inhibit the production of interleukin-2, -4 and -10 in activated human lymphocytes. Basic Clin Pharmacol Toxicol. 2008;103(4):322-8.
• 42. Malheiros SV, Brito MA, Brites D, Meirelles NC. Membrane effects of trifluoperazine, dibucaine and praziquantel on human erythrocytes. Chem Biol Interact. 2000;126(2):79-95.

Publication Dates

• Publication in this collection
  30 Aug 2011
• Date of issue
  2011

History

• Received
  25 Nov 2010
• Accepted
  19 Apr 2011